Evidence map›Paper›PMID 38353551›Full record

Observational studyMicrobiology spectrum2024

Skin dysbiosis and loss of microbiome site specificity in critically ill patients.

Tilman E Klassert, Cristina Zubiria-Barrera, Luisa Denkel, Robert Neubert, Antony Schneegans, Aylina Kulle, Antje Vester, Frank Bloos, Christian Schulze, Jörg Epstude and 3 more

Open access · goldAbstract readObservational Study
In one paragraph

Observational study in Microbiology spectrum, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
2.7field-weighted citation impact, top 11% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 5 citations in OpenAlex.

  1. Trial
  2. Article
  3. Article
  4. Review
  5. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 3 institutions in 1 country.

Tilman E KlassertRespiratory Infection Dynamics, Helmholtz Centre for Infection Research - HZI Braunschweig, Braunschweig, Germany.ORCID 0000-0002-4502-5450
Cristina Zubiria-BarreraRespiratory Infection Dynamics, Helmholtz Centre for Infection Research - HZI Braunschweig, Braunschweig, Germany.
Luisa DenkelInstitute for Hygiene and Environmental Medicine, Charité - Universitätsmedizin Berlin, Berlin, Germany.
Robert NeubertRespiratory Infection Dynamics, Helmholtz Centre for Infection Research - HZI Braunschweig, Braunschweig, Germany.
Antony SchneegansZIK Septomics, Host Septomics, Jena University Hospital, Jena, Germany.
Aylina KulleZIK Septomics, Host Septomics, Jena University Hospital, Jena, Germany.
Antje VesterZIK Septomics, Host Septomics, Jena University Hospital, Jena, Germany.
Frank BloosDepartment of Anesthesiology and Intensive Care Medicine, Jena University Hospital, Jena, Germany.
Christian SchulzeDepartment of Internal Medicine I, Cardiology, Angiology, Intensive Medical Care, University Hospital Jena, Jena, Germany.
Jörg EpstudeDepartment of Hospital Hygiene, Thuringia Clinic "Georgius Agricola", Saalfeld/Saale, Germany.
Petra GastmeierInstitute for Hygiene and Environmental Medicine, Charité - Universitätsmedizin Berlin, Berlin, Germany.
Christine GeffersInstitute for Hygiene and Environmental Medicine, Charité - Universitätsmedizin Berlin, Berlin, Germany.
Hortense SlevogtRespiratory Infection Dynamics, Helmholtz Centre for Infection Research - HZI Braunschweig, Braunschweig, Germany.
Jena University Hospital · DEMedizinische Hochschule Hannover · DECharité - Universitätsmedizin Berlin · DE

Funding

Bundesministerium für Bildung und Forschung (BMBF) 03ZZ0807DDeutsche Forschungsgemeinschaft (DFG) 390874280
6 · The paper itself

Abstract

An increasing amount of evidence has linked critical illness with dysbiotic microbiome signatures in different body sites. The disturbance of the indigenous microbiota structures has been further associated with disease severity and outcome and has been suggested to pose an additional risk for complications in intensive care units (ICUs), including hospital-acquired infections. A better understanding of the microbial dysbiosis in critical illness might thus help to develop strategies for the prevention of such complications. While most of the studies addressing microbiome changes in ICU patients have focused on the gut, the lung, or the oral cavity, little is known about the microbial communities on the skin of ICU patients. Since the skin is the outermost organ and the first immune barrier against pathogens, its microbiome might play an important role in the risk management for critically ill patients. This observational study characterizes the skin microbiome in ICU patients covering five different body sites at the time of admission. Our results show a profound dysbiosis on the skin of critically ill patients, which is characterized by a loss of site specificity and an overrepresentation of gut bacteria on all skin sites when compared to a healthy group. This study opens a new avenue for further investigations on the effect of skin dysbiosis in the ICU setting and points out the need of strategies for the management of dysbiosis in critically ill patients.IMPORTANCEUnbalanced gut microbiota in critically ill patients has been associated with poor outcome and complications during the intensive care unit (ICU) stay. Whether the disturbance of the microbial communities in these patients is extensive for other body sites, such as the skin, is largely unknown. The skin not only is the largest organ of the body but also serves as the first immune barrier against potential pathogens. This study characterized the skin microbiota on five different body sites in ICU patients at the time of admission. The observed disturbance of the bacterial communities might help to develop new strategies in the risk management of critically ill patients.

Indexed as

Gastrointestinal MicrobiomeMicrobiotaBacteriaCritical IllnessDysbiosisHumanscritical illnessdysbiosisICUskin microbiome

Identifiers

PMID38353551
PMCPMC10913461
OpenAlexW4391812071

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.